Skip to main content

Table 6 Area under the curve from the ROC analysis of pCR prediction using different MRI measures

From: RETRACTED ARTICLE: Diffusion-weighted MR imaging of locally advanced breast carcinoma: the optimal time window of predicting the early response to neoadjuvant chemotherapy

AUC

ADC at baseline

ADC at the ideal time point during chemotherapy

â–³ADC from baseline to the ideal time point during chemotherapy

Started with taxanes

 Luminal A

0.556(0.513~ 0.612)

0.598(0.546~ 0.636)

0.678(0.598~ 0.749)

 Luminal B

0.558(0.525~ 0.623)

0.602(0.567~ 0.645)

0.865(0.748~ 0.930)

 Basal-like

0.543(0.503~ 0.605)

0.589(0.558~ 0.649)

0.723(0.614~ 0.843)

 HER2-enriched

0.537(0.521~ 0.619)

0.593(0.549~ 0.638)

0.745(0.678~ 0.832)

Started with anthracyclines

 Luminal A

0.545(0.521~ 0.598)

0.587(0.529~ 0.620)

0.845(0.769~ 0.920)

 Luminal B

0.598(0.534~ 0.628)

0.612(0.528~ 0.656)

0.723(0.678~ 0.789)

 Basal-like

0.612(0.567~ 0.654)

0.621(0.557~ 0.678)

0.756(0.698~ 0.845)

 HER2-enriched

0.578(0.543~ 0.626)

0.614(0.551~ 0.636)

0.734(0.658~ 0.798)

Started with anthracyclines and taxanes

 Luminal A

0.534(0.509~ 0.589)

0.567(0.546~ 0.600)

0.738(0.645~ 0.798)

 Luminal B

0.545(0.502~ 0.620)

0.587(0.538~ 0.621)

0.756(0.655~ 0.809)

 Basal-like

0.578(0.527~ 0.600)

0.602(0.567~ 0.629)

0.879(0.789~ 0.923)

 HER2-enriched

0.602(0.526~ 0.645)

0.623(0.569~ 0.667)

0.783(0.698~ 0.823)

  1. Note: The data in the parentheses were 95% confidence intervals